Please Wait...

Lipoprotein A Lp(a)

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Lp(a) is a macromolecular complex composed of one molecule of Low-Density Lipoprotein (LDL) containing apolipoprotein B100 and one molecule of apolipoprotein(a). Lp(a) is synthesized by the liver and its assembly occurs at the hepatocyte cell membrane surface. Lp(a) has been shown to promote thrombosis, by preventing the conversion of plasminogen to plasmin and to participate to wound healing and tissue repair (Riches and Porter, 2012). Lp(a) has also been described as an acute-phase reactant in various disorders. High levels of Lp(a) correlates with an increased risk of cardiovascular diseases and are found in patients with Rheumatoid Arthritis (Govindan et al., 2015; Saeedi and Frohlich, 2016).

Bioclinica Lab employs uses the quantitative immunoturbidimetry method for the measurement of human Lp(a) in serum.

Govindan, K.P.S., Basha, S., Ramesh, V., Kumar, C.N., and Swathi, S. (2015). A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects. J. Pharm. Bioallied Sci. 7, S22–S25.

Riches, K., and Porter, K.E. (2012). Lipoprotein(a): Cellular Effects and Molecular Mechanisms. Cholesterol 2012, e923289.

Saeedi, R., and Frohlich, J. (2016). Lipoprotein (a), an independent cardiovascular risk marker. Clin. Diabetes Endocrinol. 2, 7.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Join Bioclinica in a live #Xtalks webinar 10/31 exploring challenges & benefits of different sourcing models to man… https://t.co/kRYNc1Z3gj
bioclinica (3 hours ago)
Bioclinica contributions toward advancement of #Alzheimer's disease research & therapies showcased in 8 different s… https://t.co/j96UN9568o
bioclinica (9 hours ago)
Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (Yesterday)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (Yesterday)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (Yesterday)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (Yesterday)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner